Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?

Table 1 Baseline characteristics of 4133 patients

	Eradication group (n = 3781)	Non-eradication group (n = 352)
Male/Female	2715/1066	249/103	P = 0.671
Male (%)	71.80	70.70
Mean age	52.4 ± 12.7	58.1 ± 12.6	P < 0.0012
Min-max	13.2-85.9	22.2-91.9
Age (yr)			P < 0.0011
< 60	2732 (72.3)	186 (52.8)
60-70	701 (18.5)	102 (29.0)
> 70	348 (9.2)	64 (18.2)
Location of ulcer			P = 0.411
GU	2048 (54.2)	195 (55.4)
GDU	418 (11.1)	45 (12.8)
DU	1265 (33.5)	110 (31.3)
Unknown	50 (1.3)	2 (0.6)
Salt consumption			P < 0.0011
Restricted	1377 (36.4)	173 (49.1)
No interest in salt consumption	729 (19.3)	29 (8.2)
Not restricted	1185 (31.3)	105 (29.8)
Unknown	490 (13.0)	45 (12.8)
Smoking history			P < 0.0011
Non-smokers	1174 (31.0)	120 (34.1)
Past smokers	565 (14.9)	48 (13.6)
Current smokers	1931 (51.1)	159 (45.2)
Unknown	111 (2.9)	25 (7.1)
Mean duration of follow-up (yr)	5.6 ± 1.1	5.2 ± 1.8	P < 0.0012
Min-max	0.09-7.96	0.11-8.41

¹χ² test;

²t test. Eradication group: patients who received Helicobacter pylori eradication therapy with or without successful eradication. Non-eradication group: Patients who received conventional antacid therapy. GU: Gastric ulcer; GDU: Gastroduodenal ulcer; DU: Duodenal ulcer.